Abbott Laboratories hopes to lower costs, fend off new threats, and grow in point-of-care with recent acquisition spree

In the past three months, Abbott Laboratories announced two seemingly unrelated mega acquisitions. First, in February, the company agreed to purchase Alere, a global leader in the growing point-of-care (POC) diagnostic market, for $5.8 billion. Then, in late April, it went after St. Jude Medical,...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

The continuous glucose monitoring pricing dilemma for Type 2 diabetes

Case Study | May 14, 2021

Kaiser Health News recently published an article calling into question the efficacy of minimally invasive continuous glucose monitoring (CGM) solutions for non‑insulin‑treated Type 2 diabetic patients. These CGM solutions are inserted under the skin and typically measure interstitial glucose levels... Not part of subscription

Digital tool pricing analysis: Chronic kidney disease management

Analyst Insight | May 19, 2021

Chronic Kidney Disease (CKD) The digital transformation of healthcare is enabling more effective ways of managing disease, and chronic kidney disease is no exception. The U.S. CDC estimates that 40% of people with severely reduced kidney function do not know they have it, as the symptoms are ... Not part of subscription

Digital twin technology from Twin Health bags $140 million in Series C round for diabetes care

News Commentary | October 08, 2021

The global cost of Type 2 diabetes is estimated to be more than $1 trillion annually. This is alarming, as diabetes can be well‑managed if detected early. However, diabetes presents very differently in different populations due to genetic, lifestyle, nutritional, and environmental factors. Twin ... Not part of subscription